__timestamp | Exelixis, Inc. | Johnson & Johnson |
---|---|---|
Wednesday, January 1, 2014 | 50829000 | 21954000000 |
Thursday, January 1, 2015 | 57305000 | 21203000000 |
Friday, January 1, 2016 | 116145000 | 19945000000 |
Sunday, January 1, 2017 | 159362000 | 21420000000 |
Monday, January 1, 2018 | 206366000 | 22540000000 |
Tuesday, January 1, 2019 | 228244000 | 22178000000 |
Wednesday, January 1, 2020 | 293355000 | 22084000000 |
Friday, January 1, 2021 | 401715000 | 20118000000 |
Saturday, January 1, 2022 | 459856000 | 19046000000 |
Sunday, January 1, 2023 | 542705000 | 20112000000 |
Monday, January 1, 2024 | 492128000 | 21969000000 |
In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of operational efficiency. This analysis compares the SG&A expenses of two industry giants: Johnson & Johnson and Exelixis, Inc., from 2014 to 2023.
Over the past decade, Johnson & Johnson has maintained a robust SG&A expense profile, averaging around $21 billion annually. Despite fluctuations, their expenses have shown a slight downward trend, indicating improved efficiency in managing operational costs.
In contrast, Exelixis, Inc. has seen a dramatic increase in SG&A expenses, growing by over 900% from 2014 to 2023. This surge reflects the company's aggressive expansion and investment in growth strategies.
While Johnson & Johnson showcases stability, Exelixis, Inc. exemplifies dynamic growth, each with unique strategies in managing SG&A expenses.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Johnson & Johnson or Merus N.V.: Who Manages SG&A Costs Better?
Johnson & Johnson vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Breaking Down SG&A Expenses: Johnson & Johnson vs Galapagos NV
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.